Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAspirus Arise Tocilizumab IV Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedAspirus ArisePolicy N/A

    Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for intravenous tocilizumab products (Actemra, Avtozma, Tofidence) for Aspirus Medicare Plans, including indication- and dosing-based authorization rules and preferred product step therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAspirus Arise
    PolicyInflammatory Conditions - Tocilizumab Intravenous Products Utilization Management
    Policy CodePolicy N/A
    Change TypeMaterial changes: preferred biosimilar step addedage-based initial approval requirements added
    Effective DateJan 1, 2021
    Last ReviewApr 23, 2025
    Next Review DateApr 23, 2025
    Key ActionPrior authorization required; prescribers should document indication, prior therapies, age, and objective response when requesting non-preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    Updated policy statement to indicate that the acute treatment of COVID-19 in hospitalized patients is not addressed in this policy.

    UCare added a preferred biosimilar step with Tyenne as the preferred biosimilar before Actemra and Tofidence for patients new to therapy effective 1/1/2025.

    Condition-specific age requirements were added for initial approvals across multiple indications (e.g., ≥18 for giant cell arteritis, RA initial approvals, polymyalgia rheumatica; ≥2 for SJIA and polyarticular JIA).

    Tyenne (biosimilar to Actemra Intravenous) was added to the policy with the same criteria as Actemra Intravenous.

    Policy renamed to Inflammatory Conditions - Tocilizumab Intravenous Products and wording changed from Actemra to tocilizumab throughout the policy.

    Tofidence intravenous was added to the policy with the same criteria as other tocilizumab intravenous products.

    Giant cell arteritis and several other indications now include explicit minimum age requirements (e.g., ≥18 years for multiple conditions; ≥2 years for polyarticular juvenile idiopathic arthritis).

    Updated step therapy to require clinical need for non-preferred product over preferred products, including chart note documentation to support the need.

    Selected revisions added or clarified indications and examples (e.g., CAR T-cell therapies examples, AOSD/SJIA alignment, biosimilar counting rules).

    Allplans governed
    3products listed
    Tyennepreferred step
    6 mo → 1 yrtypical durations
    800 mgdose cap
    Not recommendedCOVID-19 coverage stance

    Coverage Criteria and Indication-specific Rules

    Cytokine Release Syndrome (CAR T-cell therapy)

    Approve when BOTH dosing and duration conditions are met

    CRS Authorization: 1) Each individual dose must meet ONE of the following: (i) patient < 30 kg: up to 12 mg/kg to a maximum of 800 mg per dose; OR (ii) patient ≥ 30 kg: up to 8 mg/kg to a maximum of 800 mg per dose. AND 2) Approve up to four doses if there will be an interval of at least 8 hours between doses.up to 4 doses; interval ≥ 8 hours

    Approve for 1 week duration (adequate to receive four doses)

    Giant Cell Arteritis

    Approve when ONE of the following initial or continuation pathways is met

    GCA Initial Therapy: Initial Therapy: Approve for 6 months if ALL: i) patient is > 18 years of age; AND ii) patient has tried or is currently taking a systemic corticosteroid (unless contraindicated); AND iii) medication is prescribed by or in consultation with a rheumatologist.6 months

    Example corticosteroid: prednisone

    GCA Continuation Therapy: Patient is currently receiving a tocilizumab subcutaneous or intravenous product: Approve for 1 year if BOTH: i) established on therapy ≥ 6 months; AND ii) meets at least ONE: (a) beneficial clinical response by at least one objective measure (e.g., CRP, ESR, resolution of fever, reduced corticosteroid dose), OR (b) improvement in at least one symptom (e.g., decreased headache, scalp/jaw pain, fatigue, improved vision).1 year

    Dosing: up to 6 mg/kg to maximum 600 mg per dose; interval at least 4 weeks between doses.

    Polyarticular Juvenile Idiopathic Arthritis (pJIA)

    Approve when ONE of the following initial or continuation pathways is met

    pJIA Initial Therapy: Initial Therapy: Approve for 6 months if ALL: i) patient is > 2 years of age; AND ii) patient meets ONE of: a) tried one other systemic therapy for this condition (examples: methotrexate, sulfasalazine, leflunomide, NSAID, or a biologic counts as a trial); OR b) starting tocilizumab IV concurrently with methotrexate/sulfasalazine/leflunomide; OR c) absolute contraindication to those agents; OR d) aggressive disease as determined by the prescriber; AND iii) medication is prescribed by or in consultation with a rheumatologist.6 months

    A biologic counts as a trial of one systemic therapy; examples of absolute contraindications to methotrexate include pregnancy, breastfeeding, alcoholic liver disease, immunodeficiency, blood dyscrasias.

    pJIA Continuation Therapy: Patient is currently receiving a tocilizumab intravenous or subcutaneous product: Approve for 1 year if BOTH: i) established on therapy ≥ 6 months; AND ii) meets at least ONE: (a) beneficial clinical response by at least one objective measure (e.g., MD global, PGA, PDA, JDAS/cJDAS, JSpADA, CRP, ESR, steroid dose reduction), OR (b) improvement in at least one symptom (e.g., improved motion, less joint pain, decreased morning stiffness, decreased fatigue, improved function).1 year

    Rheumatoid Arthritis

    Approve when ONE of the following initial or continuation pathways is met

    RA Initial Therapy: Initial Therapy: Approve for 6 months if ALL: i) patient is > 18 years of age; AND ii) patient has tried ONE conventional synthetic DMARD for at least 3 months (examples: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine); an exception may be made if the patient has already had a 3-month trial of at least one biologic; AND iii) medication is prescribed by or in consultation with a rheumatologist.6 months

    A patient who has already tried a biologic is not required to 'step back' to a conventional DMARD.

    RA Continuation Therapy: Patient is currently receiving a tocilizumab intravenous or subcutaneous product: Approve for 1 year if BOTH: i) established on therapy ≥ 6 months; AND ii) meets at least ONE: (a) beneficial clinical response by at least one objective measure (e.g., CDAI, DAS28-ESR/CRP, PAS-II, RAPID-3, SDAI), OR (b) improvement in at least one symptom (e.g., decreased joint pain, morning stiffness, fatigue, improved function, decreased swelling).1 year

    Dosing: up to 8 mg/kg to a maximum of 800 mg per dose with an interval of at least 4 weeks between doses.

    Indication-specific approval criteria (selected)

    Coverage is allowed when indication-specific AND/OR criteria are met; initial approvals often require age and prescriber requirements plus prior therapy trials; continuation approvals require established therapy duration and evidence of benefit.

    Pediatric/Adult dosing general: Each individual dose must meet one of the weight-based dosing rules and meet the specified minimum dosing interval for the indication.see dosing thresholds per indication (examples: <30 kg up to 10–12 mg/kg; ≥30 kg up to 8 mg/kg; adult max 800 mg); intervals vary (1 week to 4 weeks)

    Refer to indication-specific dosing limits and intervals

    Rheumatoid arthritis (summary): Approve when patient meets ONE of: A) Initial Therapy for 6 months when ALL: patient > 18 years; tried one conventional synthetic DMARD ≥ 3 months (exception if prior biologic trial exists); prescribed by/consultation with a rheumatologist; OR B) Currently receiving tocilizumab IV/SC: Approve 1 year when BOTH: established ≥ 6 months and evidence of benefit by objective measure or symptomatic improvement.see chunks 18-20

    Examples of objective measures provided in policy

    Policy-level coverage updates

    Policy-level coverage criteria updates and notes

    Biosimilar step for new-to-therapy: Patients new to therapy must try the preferred biosimilar (Tyenne) before non-preferred tocilizumab products unless clinical need is documented.preferred biosimilar first for new-to-therapy

    Chart note documentation required to justify bypass of preferred biosimilar

    Age requirements for initial approval: Specific indications have minimum age requirements (examples: ≥18 years for adult conditions; ≥2 years for polyarticular juvenile idiopathic arthritis).age-based

    Applies to initial approvals as specified per indication

    Condition-specific additions/clarifications: Examples and notes updated for CAR T-cell therapies and bispecific antibody CRS, SJIA/AOSD alignment clarified, Castleman disease HIV/HHV8 requirements added, and Tofidence intravenous and Tyenne biosimilar added with same criteria as other tocilizumab IV products.

    The policy does not address the acute treatment of COVID-19 in hospitalized patients. Prior authorization is recommended for tocilizumab intravenous products overall, but any requests for tocilizumab used specifically as acute therapy for hospitalized COVID-19 patients fall outside the scope of this policy and should be managed per institutional protocols or relevant COVID-19–specific guidance.

    Coverage of tocilizumab intravenous products is not recommended for COVID-19 except for the narrow hospitalized adult indication described in product labeling (hospitalized adults receiving systemic corticosteroids who require supplemental oxygen, non‑invasive or invasive ventilation, or ECMO). The policy also lists concurrent use with another biologic or with a targeted synthetic oral small molecule drug for inflammatory conditions as not recommended. Requests for uses not listed in the Recommended Authorization Criteria (for example, Crohn's disease) are likewise not recommended without stronger evidence.

    Wording for COVID-19 exclusions was revised to clarify that the policy excludes the acute treatment of COVID-19 in hospitalized patients from its coverage guidance. Operationally, the policy also updated corticosteroid trial language (now requiring the patient has tried or is currently taking a systemic corticosteroid unless contraindicated) where relevant to indications that reference corticosteroid use.

    Coverage for tocilizumab intravenous products is not recommended for Crohn's disease at this time. The policy cites a single 12‑week pilot study with limited sample size and inconclusive results and therefore deems the current evidence insufficient to support routine approval for this indication.

    The policy specifies that concurrent administration of tocilizumab with another biologic or with a targeted synthetic oral small molecule drug for inflammatory conditions is not recommended and may trigger denial of authorization. This concurrent use exclusion was highlighted in the history as a clarified policy-level change and remains a common denial trigger.

    Neutral / referencedmixed
    affected codespolicy references dosing and product-specific rules; exact billing codes not present in this excerpt

    Dosing, Age Limits, and Code References

    Tocilizumab products (listed by name)mixed
    ActemraTocilizumab intravenous product (Actemra)
    TyenneTyenne (biosimilar to Actemra Intravenous)
    TofidenceTofidence intravenous tocilizumab product
    AvtozmaAvtozma (tocilizumab intravenous product)
    Weight-based dosing thresholds — Dose rules vary by weight with maximum per-dose caps
    Weight-based rulesDose rules differ by patient weight: for patients <30 kg dosing allowances up to 10–12 mg/kg (indication-dependent) with per-dose maxima commonly up to 800 mg; for patients ≥30 kg dosing allowances up to 8 mg/kg with per-dose maxima up to 800 mg.
    Maximum per-dose caps (examples)Common adult maximum per dose appears as 800 mg; select indications (e.g., GCA) list a 600 mg maximum per dose when noted.
    Indication-specific weight tiersCRS and bispecific-antibody–associated CRS: <30 kg up to 12 mg/kg (max 800 mg); ≥30 kg up to 8 mg/kg (max 800 mg).
    pJIA pediatric dosing exampleFor polyarticular JIA: <30 kg up to 10 mg/kg (max 800 mg); ≥30 kg up to 8 mg/kg (max 800 mg).
    Intervals between doses — Intervals specified by indication (e.g., ≥8 hours between CRS doses; maintenance dose intervals)

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required — Indication-Specific and Age-Based Criteria

    Prior Authorization is recommended for medical benefit coverage of tocilizumab intravenous products. Approval is recommended only when patients meet indication-specific criteria (age, prior therapies, prescriber specialty, and demonstrated clinical response or symptom improvement) as detailed in the FDA-Approved Indications and Other Uses sections. Initial approvals require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated. Initial age requirements apply for multiple indications (e.g., ≥18 years for many adult indications; ≥2 years for polyarticular juvenile idiopathic arthritis and other pediatric-specific indications).

    • Prior authorization applies to Actemra, Avtozma, and Tofidence (Tyenne is the preferred product)
    • Initial approvals require prescriber specialty consultation (physician who specializes in the condition)
    • Indication-specific age requirements must be met for initial approvals (see policy indication details)
    Step Therapy

    Preferred Biosimilar Step Therapy for New-to-Therapy Patients

    Background and Scope

    Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor used to treat multiple inflammatory conditions, including cytokine release syndrome (CRS) related to CAR T‑cell therapy, giant cell arteritis, systemic and polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis. Dosing and monitoring are indication‑specific and include weight‑based dose rules and laboratory‑guided dose interruption/modification for abnormalities.

    Definitions, Dosing Guidance, and Abbreviations

    Tocilizumab (IV) — IL-6 receptor inhibitor examples: Actemra, Avtozma, Tofidence
    Tocilizumab (IV) descriptionAn interleukin-6 (IL-6) receptor inhibitor administered intravenously used to treat multiple inflammatory conditions including CRS, giant cell arteritis, JIA, RA, and SJIA.
    Examples of branded productsActemra is the reference tocilizumab product; biosimilars and IV formulations such as Actemra IV and listed biosimilars are included in the appendix.
    Additional product names in policyPolicy references other tocilizumab intravenous products (e.g., Avtozma, Tofidence) alongside Actemra and biosimilars.
    Dose interruption/modification — Guidance for lab abnormalities and following RA guidance
    Lab‑based dose interruption/modificationDose interruptions or modifications are recommended for laboratory abnormalities (e.g., increased liver enzymes, neutropenia, thrombocytopenia) and dosing modifications generally follow guidance used in rheumatoid arthritis; specific modifications are determined by the prescriber.
    Policy Summary
    PayerAspirus Arise
    PolicyInflammatory Conditions - Tocilizumab Intravenous Products Utilization Management
    Policy CodePolicy N/A
    Change TypeMaterial changes: preferred biosimilar step addedage-based initial approval requirements added
    Effective DateJan 1, 2021
    Last ReviewApr 23, 2025
    Next Review DateApr 23, 2025
    Key ActionPrior authorization required; prescribers should document indication, prior therapies, age, and objective response when requesting non-preferred products.
    SourceLink
    On This Page
    Coverage Criteria and Indication-specific RulesDosing, Age Limits, and Code ReferencesPrior Authorization, Step Therapy, and Documentation RequirementsBackground and ScopeDefinitions, Dosing Guidance, and Abbreviations

    Dosing: <30 kg: up to 10 mg/kg to a maximum of 800 mg per dose; ≥30 kg: up to 8 mg/kg to a maximum of 800 mg per dose; interval ≥ 4 weeks between doses.

    Systemic juvenile idiopathic arthritis (SJIA): Initial Therapy: Approve 6 months when BOTH: patient > 2 years; medication prescribed by or in consultation with a rheumatologist. Continuation: Approve 1 year when BOTH: established on therapy ≥ 6 months; and benefit demonstrated by objective measure OR symptomatic improvement.see chunks 20 and 21

    SJIA and AOSD are considered the same disease differing by age of onset

    Castleman disease: Initial Approval: Approve 6 months when ALL: patient > 18 years; if unicentric disease patient is negative for HIV and HHV8; medication prescribed by or in consultation with an oncologist or hematologist. Continuation: Approve 1 year when BOTH: established on therapy ≥ 6 months; and benefit by objective measure OR symptomatic improvement.see chunk 22

    Objective measures examples include CRP, ESR, fibrinogen, albumin, hemoglobin, BMI, reduction in lymphadenopathy

    Cytokine release syndrome (bispecific antibodies): Approve for 1 week (adequate for four doses) when patient has been or will be treated with a bispecific antibody. Dosing: weight-based up to 12 mg/kg (<30 kg) or 8 mg/kg (≥30 kg) max 800 mg; up to four doses with at least 8 hours between doses.up to 4 doses; interval ≥ 8 hours

    Examples of bispecific antibodies provided in policy

    Graft-versus-host disease (acute): Initial Therapy: Approve 1 month when ALL: patient ≥ 18 years; acute GVHD; tried at least one systemic medication for GVHD; medication prescribed by/consultation with oncologist, hematologist, or transplant-affiliated physician. Continuation for IV product: Approve 3 months when BOTH: established on therapy ≥ 1 month; and benefit by objective measure OR symptomatic improvement.see chunks 23-24

    Examples of systemic medications provided

    Immunotherapy-related toxicities (checkpoint inhibitors): Initial Therapy: Approve 6 months when ALL: patient > 18 years; prescriber states immunotherapy-related toxicity developed on checkpoint inhibitor; symptomatic despite trial of at least one systemic corticosteroid; medication prescribed by/consultation with appropriate specialist. Continuation for IV product: Approve 1 year when BOTH: established ≥ 6 months; and benefit by objective measure OR symptomatic improvement.see chunks 25-26

    Objective measures depend on organ involvement

    Polymyalgia rheumatica: Initial Therapy: Approve 6 months when ALL: patient > 18 years; tried one systemic corticosteroid; prescribed by/consultation with a rheumatologist. Continuation for IV/SC: Approve 1 year when BOTH: established ≥ 6 months; and benefit by objective measure OR symptomatic improvement.see chunk 27

    Objective measures include CRP, ESR, resolution of fever, or corticosteroid reduction

    Adult-onset Still's disease (AOSD): Initial Therapy: Approve 6 months when BOTH: patient > 18 years; medication prescribed by/consultation with a rheumatologist. Continuation: Approve 1 year when BOTH: established on therapy ≥ 6 months; and benefit by objective measure OR symptomatic improvement.see chunks 28-29

    AOSD and SJIA considered same disease differing by age

    VEXAS syndrome: Initial Therapy: Approve 6 months when ALL: patient ≥ 18 years; molecular genetic test demonstrating pathogenic or likely pathogenic UBA1 variant; patient has tried or is currently taking systemic corticosteroid or corticosteroids are contraindicated; medication prescribed by/consultation with appropriate specialist. Continuation: Approve 1 year when BOTH: established ≥ 6 months; and benefit by objective measure OR symptomatic improvement.see chunks 29-30

    Objective measures examples include resolution of fever, skin improvement, CRP/ESR normalization, corticosteroid reduction

    policy-level clarifications

    See full policy for complete indication-level criteria and history

    CRS dosing intervalFor Cytokine Release Syndrome (CAR T-cell therapy) and bispecific-antibody CRS: allow up to four doses provided there is an interval of at least 8 hours between doses.
    Maintenance/typical intervalsMost chronic indications (e.g., GCA, pJIA, RA) require intervals of at least 4 weeks between maintenance IV doses.
    Shorter interval examplesSome indications and dosing regimens allow 1-week or 2-week intervals (e.g., select supportive‑evidence uses specify 1 week or 2 weeks as the minimum interval).
    Dose and interval thresholds — Multiple weight-based maxima and minimum intervals (examples provided)
    Example: CRS / bispecific-antibody CRSEach dose must meet weight-based limits ( <30 kg: up to 12 mg/kg to max 800 mg; ≥30 kg: up to 8 mg/kg to max 800 mg) and up to four doses may be approved if intervals ≥8 hours between doses.
    Example: Polyarticular JIA dosing<30 kg: up to 10 mg/kg (max 800 mg) per dose; ≥30 kg: up to 8 mg/kg (max 800 mg); interval ≥4 weeks.
    Example: Giant Cell Arteritis dosingDosing for GCA references up to 6 mg/kg to a maximum of 600 mg per dose with an interval of at least 4 weeks between doses (per continuation criteria note).
    Example: Still's disease / AOSD/SJIASelect uses: approve up to 6 mg/kg (max 600 mg) with interval of at least 4 weeks for some presentations; other presentations use up to 8 mg/kg with interval 2–4 weeks depending on indication.
    Age thresholds for initial approval — e.g., ≥18 years for many adult indications; ≥2 years for polyarticular JIA
    Adults (most adult indications)Minimum age threshold commonly ≥18 years for initial approval (examples: giant cell arteritis, RA, polymyalgia rheumatica, AOSD, VEXAS).
    Pediatric (pJIA, SJIA)Polyarticular JIA and systemic JIA initial approvals specify patients ≥2 years of age for treatment eligibility.
    CRS age criteriaCRS associated with CAR T-cell therapy: indication includes patients ≥2 years of age for severe or life-threatening disease in the overview; authorization criteria reference appropriate dosing by weight rather than a higher adult-only age limit.

    A preferred biosimilar (Tyenne) is required as the first-line product for patients who are new to therapy effective 01/01/2025. For patients new to therapy, authorization for non-preferred products (Actemra, Avtozma, Tofidence) will be granted only if the patient meets one of the step therapy exceptions or documents clinical need. For patients who are not new to the requested non-preferred product (used within prior 365 days), the step does not apply.

    • Effective 01/01/2025: Tyenne is the preferred biosimilar for new-to-therapy patients
    • Non-preferred products: Actemra, Avtozma, Tofidence
    • New-to-therapy defined as no use of the requested product in the previous 365 days
    Step Therapy

    Preferred Product Step Therapy — Exceptions and Required Documentation

    Authorization for a non-preferred biologic product or biosimilar will be granted only if the patient meets at least one of the listed exceptions. Chart notes documenting the applicable exception must be provided at the time of request. Factors such as patient or prescriber preference or inability to stock the preferred product will not be accepted as exceptions. Common side effects or infusion-related reactions do not qualify as documented allergic reactions.

    • Exceptions that permit approval of a non-preferred product (one of A–E must be met and documented):
    • A. Patient is not a new start to the non-preferred product (used within prior 365 days)
    • B. Allergic reaction to a specific inactive ingredient in all preferred products or biosimilars
    • C. Adverse reaction to a specific inactive ingredient in all preferred products or biosimilars
    • D. Therapeutic success on the non-preferred product AND therapeutic failure on an adequate trial of all preferred products (adequate trial generally ≥3 months)
    • E. Patient has a diagnosis included in the non-preferred product’s FDA indications but not included in the preferred products’ FDA indications
    Documentation Required

    Required Documentation at Time of Request

    At the time of request, submit chart notes documenting prior trials, allergic or adverse reactions to preferred products, contraindications, therapeutic failure, and baseline status. Documentation must support clinical need for a non-preferred product over the preferred biosimilar for new-to-therapy patients; failure to provide appropriate chart documentation may result in denial.

    • Chart notes must document: prior medication trials and durations, objective measures or symptom changes from baseline, specific allergic/adverse reactions or contraindications, and rationale for selecting a non-preferred product
    • For new-to-therapy patients, document why Tyenne (preferred biosimilar) is not appropriate or acceptable
    Documentation Required

    Clinical Response and Prescriber Documentation Requirements

    For continuation/established therapy, requests must document clinical response versus baseline using at least one objective measure or demonstrable symptom improvement (examples include disease activity scores, physician/patient global assessments, and relevant serum markers). Documentation should indicate duration of prior therapy (established on therapy ≥6 months for some indications) and meet any specialty prescriber requirements noted in the indication-specific criteria.

    • Acceptable objective measures: CDAI, DAS28 (ESR/CRP), RAPID-3, SDAI, JADAS, cJADAS, CRP/ESR, Physician/Patient Global Assessments
    • For continuation approvals: patient established on therapy ≥6 months for some indications; demonstrate beneficial clinical response or symptom improvement from baseline
    Prescriber discretionThe policy states dosing modifications are determined by the prescriber and reduced dosing in non‑RA conditions generally follows RA recommendations.
    Clinical monitoring contextRecommendations for interruption/modification are tied to management of dose‑related lab changes; refer to RA guidance for specific thresholds and actions.
    Objective measures — Standardized clinical or laboratory assessments used to document response (e.g., CDAI, DAS28, RAPID-3)
    Common disease activity scoresObjective measures include standardized disease activity scores such as CDAI, DAS28 (ESR/CRP), RAPID‑3, SDAI, and juvenile‑specific scores (JDAS, cJDAS, JSpADA).
    Laboratory markersSerum markers such as C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are cited as objective measures of response.
    Other objective signsAdditional objective measures include resolution of fever, normalization of laboratory parameters (e.g., LFTs where relevant), and reduced corticosteroid dose or improved functional status.
    Tocilizumab (Actemra and biosimilars) — Tocilizumab products referenced
    Actemra and IV biosimilarsActemra IV and its biosimilars are listed in the appendix among tocilizumab products addressed by the policy.
    SC and IV formulations notedThe appendix differentiates SC and IV formulations and lists Actemra SC and its biosimilars as related products; IV formulations are noted for indications such as PJIA, RA, SJIA.
    Additional IV products referencedPolicy also references other tocilizumab intravenous products (e.g., Avtozma, Tofidence) in the coverage scope and changes summary.
    Common abbreviations — Abbreviations used in policy (e.g., RA, JIA, SJIA, PJIA, IV, SC)
    RARheumatoid arthritis
    JIA / PJIA / SJIAJuvenile idiopathic arthritis (polyarticular JIA, systemic JIA)
    IV / SCIV = Intravenous; SC = Subcutaneous
    AOSDAdult‑onset Still's disease